PDF(Pubmed)
Abstract：
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a substantial healthcare challenge. Provoked and unprovoked DVT cases carry distinct risks and treatment considerations. Recognizing the limitations of this classification, molecular markers may enhance diagnostic precision and guide anticoagulation therapy duration relying on patient history and risk factors. This preliminary, open-label, prospective cohort study was conducted including 15 patients (10 provoked DVT and 5 unprovoked DVT) and a control group of healthy plasmatic subjects. Plasma levels of 9 biomarkers were measured at diagnosis (baseline, day 0, and D0) and after 30 days (day 30-D30). Patient demographics, clinical data, and biomarker concentrations were analyzed. Serum concentrations of D-dimer, von Willebrand factor, C-reactive protein, and Anti-Xa were elevated in DVT groups at D0 compared to controls. No significant differences were observed between the provoked and unprovoked groups on the day of diagnosis and 30 days later. Over 30 days, the provoked group exhibited significant biomarker changes related to temporal assessment. No significant differences were noted in the biomarker profile between provoked and unprovoked DVT groups. This study is indicative of the concept of individualized thrombosis assessment and subsequent treatment for VTE. Larger cohorts are warranted to validate these findings and further define the most appropriate use of the molecular markers.
摘要：
静脉血栓栓塞症(VTE),包括深静脉血栓形成（DVT）和肺栓塞（PE），这是一个巨大的医疗保健挑战。引发的和无端的DVT病例具有不同的风险和治疗注意事项。认识到这种分类的局限性，分子标志物可提高诊断精度,并根据患者病史和危险因素指导抗凝治疗持续时间.这个初步的，开放标签，进行了前瞻性队列研究，包括15例患者（10例引起的DVT和5例非引起的DVT）和健康血浆受试者的对照组。在诊断时测量9种生物标志物的血浆水平（基线，第0天和D0）和30天后（第30-D30天）。患者人口统计学，临床资料,和生物标志物浓度进行了分析。血清D-二聚体浓度,vonWillebrand因子,C反应蛋白,与对照组相比,D0时DVT组的抗Xa升高。在诊断当天和30天后，激发组和非激发组之间没有观察到显着差异。超过30天,受激组表现出与时间评估相关的显著生物标志物变化.在诱发性和非诱发性DVT组之间的生物标志物谱中没有发现显著差异。这项研究表明了个体化血栓形成评估和随后治疗VTE的概念。需要更大的群体来验证这些发现并进一步定义分子标记的最适当使用。
